Synology unveils flagship enterprise storage, cloud surveillance solutions at COMPUTEX 2025
'At Synology, our goal has always been to build a data management ecosystem our customers can trust,' said Philip Wong, Chairman and CEO of Synology. 'We design our solutions to offer not only unparalleled ease of use, but also industry-leading security, reliability, and data privacy, empowering both organisations and individuals to manage their data with confidence.'
Enterprise storage: PAS7700
Headlining Synology's enterprise offerings is the PAS7700, a flagship NVMe all-flash storage system. Featuring a dual-controller, active-active architecture, the PAS7700 is engineered for mission-critical workloads and aims to deliver non-disruptive service continuity.
The system delivers up to 2 million IOPS and sub-millisecond latency, with performance up to three times higher than previous models, according to the company. It incorporates 3-2-1-1 data replication for comprehensive data integrity and protection.
Expanding its ActiveProtect portfolio, Synology introduced the DP7200, a data protection appliance that can serve as a standalone backup server or centralised management host. It is equipped with immutability and network isolation features to protect against cyber threats and ensure recoverable backup copies.
Cloud surveillance: C2 surveillance
The company also launched C2 Surveillance, a cloud-based video management system tailored for large-scale, multi-site deployments. Designed for NVR-less installation, it offers centralised cloud management, Windows AD integration, and role-based access control. The platform supports continuous edge recording and offline failover to guarantee uninterrupted video monitoring.
The company is expanding its productivity suite with ChatPlus and Synology Meet. ChatPlus enables secure team communications with advanced permission and channel management, while Synology Meet offers enterprise-grade video conferencing. Both services run on Synology's private cloud, ensuring full control and data privacy.
Consumer cloud: BeeStation Plus
For personal users, the company debuted BeeStation Plus, a private cloud solution tailored for families. It supports automatic backup of iCloud Photo Libraries, Plex Media Server integration, and smart home surveillance features when used with Synology's CC400W camera. Additional features include intelligent event detection and local or cloud-based recovery through BeeProtect.
COMPUTEX 2025 also highlighted Synology's deepening engagement with the Indian market.
Joanne Weng, Director of the International Business Department, welcomed national distributors Esdee Business Machine Pvt. Ltd and Tech Data Advanced Pvt. Ltd, as well as system integrators and channel partners. Indian media representatives conducted interviews with Synology executives, underscoring the company's growing presence and influence in the region.
In an exclusive interview with Arabian Business, Weng also revealed that the Middle East is emerging as one of the company's fastest-growing markets.
'The Middle East is definitely one of the top growth markets,' she said. 'We didn't really start focusing on the Middle East until very recently. With us investing a bit more into the market, putting more focus, having our main people present, we are already getting tons of inquiries and requirements.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
a day ago
- Zawya
Bora Pharmaceuticals 2Q25 Operating Margin Expanded 5 Percentage Points, Reaching Quarterly High Since The Start of Integration in 4Q24; Strong Momentum Poised to Accelerate in 2H25 As Operational Efficiency Gains Materialize
HONG KONG SAR - Media OutReach Newswire - 8 August 2025 - Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for second quarter of 2025. Quarterly Business and Financial Highlights · Company reported quarterly basic EPS of NT$5.95, with NT$1.81 from discontinued operations. OPEX was ~15% below guidance, aided by a ~4% FX gain. Gross margin was impacted by ~4% due to lower CDMO utilization. · FX loss totaled at ~NT$252 million in 2Q25, or NT$2.4 per share; Excluding FX impact from operational to non-OP, core EPS would have reached approximately NT$8.08, second highest on record after 1Q23, excluding all M&A related non-operating gains. · Fueled by expanded capacity and new dosage forms, Bora's CDMO business in 1H25, including internal orders, grew 69.5% compared to same period last year, reaching more than NT$5.01 billion, and yet posted a 26.6% sequential decline during the quarter due to slower momentum navigating through transitional integration phase mainly at sterile injectable site in Maryland and Zhunan facility with no impact on long-term fundamentals. · Pharma Sales revenues in 1H25 rose 23.0% YoY based on reported unaudited monthly sales, driven by market share expansion of the vigabatrin franchise across three dosage forms. VIGAFYDE uptake continued its acceleration during the quarter, supporting momentum into 2H25. · The Group observed robust CDMO order momentum in 3Q25, supported by a more streamlined and disciplined operating structure. With this solid execution base in place, Bora is confident that core profitability will resume. As CDMO growth accelerates through expanded U.S.-based capacity and capabilities in the near future, Bora shall be positioned for the next inflection point. · Share capital increased 0.25% during the quarter from employee stock option exercises and convertible bond conversions. Company went ex-rights on August 4 with book closure and record date both on August 10. · The Board approved setting up Bora Global Ltd., a wholly owned BVI subsidiary of Bora, and the injection of US$40mn in eye of fluctuating FX and other geo political nuances to reduce the Company's USD exposure. Mr. Bobby Sheng, Chairman of Bora Group, stated, "The second quarter marks our transition out of the integration phase that began in 4Q24 with stronger operational cash inflow. To further enhance our resilience to geopolitical and currency fluctuations, we have confirmed the establishment of Bora Global Ltd., a wholly owned BVI subsidiary. The planned injection of US$40 million into this entity reflects a proactive step to reduce the Company's USD exposure and strengthen financial flexibility amid ongoing macro uncertainties. Following multiple business and capacity acquisitions last year, we are proud to have established a solid foundation for operational efficiency gains and scalable growth in our change-enabling CDMO business and service-model oriented specialty pharma expansion. Looking ahead, Bora will advance its focus on high-value and complex dosage forms supported by ample cash on hand to grow our CDMO business. As of 2Q25, around 80% of our 2025 CAPEX plan has been deployed. One of the key investments include a high-performance filling line at our Canada site in Mississauga which enables larger volumes at higher speeds with greater flexibility, particularly for dermatologic products. The investment comes as the global dermatology drugs market is projected to nearly double in value to over $70 billion by 2030, reflecting the rising demand for high-quality, specialized treatments. In addition, while Flex-Pro line at our sterile injectable site in Maryland is expected to enter commercial stage production in 3Q25, while state-of-the-art isolated fill-finish system of automated vial, syringe, and cartridge filling line for the cGMP multi-product production of potent and targeted parenteral pharmaceuticals will take place over the course of 2026. Last but not least, year-to-date, we've added 8 new clients to our CDMO network, mostly for Maple Grove site in Minnesota. Newly added order backlog in 2025 increased to US$138 million. Majority of the contracts, in value, belongs to Canadian site and sterile injectable facility with orders from anchor new clients. On pharma sales side, specialty pharma business significantly outperformed expectations, with the vigabatrin franchise achieving double digit growth in market share. In the second half of the year, we plan to continue investing in channel marketing and strengthening engagement with key stakeholders on the payer side. The revenue mix between specialty pharma and generics reached 35% vs. 65% during the quarter, marking Bora's official transition into a specialty pharma company. Moving forward, we will focus on strengthening our presence in Ready-to-Use forms of dosages in the rare and underserved DEE (Developmental and Epileptic Encephalopathies) space through both in-licensing and proprietary R&D, enabling more efficient resource allocation and return in a market where me-too products have been under increasing pressure. This is part of Bora's ongoing transformation toward a more white-glove, service-oriented model across both pharma sales and CDMO, sharpening our strategic focus on high-demand, value-driven markets to scale, integrate, and synergize" 2Q2025 Operational Achievements & Full Year Outlook Global CDMO Operations Global CDMO Operations (excluding internal orders) revenues arrived at NT$1.59 billion in the second quarter, up 14.8% YoY and representing approximately 32.7% of total revenue. Including internal orders, CDMO revenue reached NT$5.01 billion. A total of 548 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 32%. Bora continues to execute on expanding this customer base to enhance business visibility and stability. · In 1H25, the small molecule and sterile CDMO pipeline added US$138 million in backlog, marking historic high. · While the Company ramps up its Maple Grove site, it is seeing encouraging momentum - clinical-stage clients are transitioning to long-term strategic partnerships. In parallel, Bora observes a steady uptick in contract signings from pharmaceutical companies looking to secure US domestic manufacturing. Discussions remain active with potential anchor clients and the Company is planning the initiation of small molecule packaging line build-out as the first step in our capacity pre-sell strategy. · Large molecule CDMO operation was launched following the January 20 reverse-acquisition of Bora Biologics by Tanvex Biopharm where Bora owns 30.5% of Tanvex. CDMO operations at the San Diego site are now active, and the ongoing 2,000L expansion has received strong interest from late-stage clients with half of the potential deals from US clients. Pharma Sales Operations Pharma Sales Operations revenue reached NT$3.26 billion, down 10.4% YoY, primarily due to discontinuing several products under significant pricing pressure. Pharma Sales accounted for approximately 67.0% of total revenues. · Bora identified a shift from DRE (Drug Resistant Epilepsy) to DEE (Developmental and Epileptic Encephalopathies) in the epilepsy market since the acquisition of Upsher-Smith and validated, through field work of sales and marketing, that legacy compounds fall short in addressing the significant unmet needs in this segment. Approved treatments were only available for epilepsies related to Dravet Syndrome, Lennox-Gastaut Syndrome, TSC (Tuberous Sclerosis Complex) and CDKL5 deficiency at the moment, meaning more NCEs will come in the near future, further enlarging the addressable market. The Company expects to capture the sizable opportunities of approximately US$ 10 billion in the next 3 to 5 years building a sound pipeline with Ready-to-Use 505(b)(2) such as Stiripentol, USL551, and at least 2 more compounds. Bora continues to await regulatory approval for 3 high-value generics in our pipeline in the remainder of the year. Recent Investor Conference Bora will host an English online earnings call at 6:00 p.m. Taiwan time on Aug. 8, 2025, followed by an investor conference hosted by Taishin Securities at the Grand Hyatt Taipei at 2:30 p.m. on Aug. 12, 2025. Both events will cover the company's Q2'25 financial and business results and outlook. 🔗 English Online Earnings Presentation Link: Bora will participate in the Daiwa Consumer and Healthcare Conference on Sept. 3-4 in Hong Kong and Goldman Sachs CDMO Day on Sept. 16-17 in Singapore. For 1:1 meetings with management, please contact your Daiwan and Goldman Sachs representative. Bora 2025 Earnings Schedule Q3 2025: Expected in the 3 rd week of November 2025 Q4 2025: Expected in the 2 nd week of March 2026 Hashtag: #BoraPharmaceuticals The issuer is solely responsible for the content of this announcement. About Bora: Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life. By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. For more information, please visit: Disclaimer: This document and the accompanying information may contain forward-looking statements. All statements regarding the company's future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company's control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates. Bora Pharmaceuticals
Zawya
2 days ago
- Zawya
Foreigners pour billions into Taiwan, South Korea stocks on AI, growth optimism
Foreign investors flocked to Asian stocks for the third straight month in July, with inflows into Taiwan hitting a near two-decade high and Thailand snapping its nine-month losing streak, buoyed by growth and AI prospects as trade worries fluctuate. Foreign inflows into most Asian equity markets have stabilised over the past three months as countries clinched better trade arrangements with the United States, calming tariff-related volatility and uncertainty in financial markets. Overseas investors showed strong interest in Taiwan and South Korea for the third straight month in July, pouring $7.78 billion in Taiwan, the highest since the 2008 global financial crisis, and $4.52 billion in South Korea, the most since February last year, LSEG data showed. The MSCI gauge of equities in Asia excluding Japan rose 2% last month, its fifth consecutive month in green, while benchmarks in Taipei and Seoul advanced roughly 6% each. Taiwan and South Korea were the top destinations in the region for foreign capital, securing a cumulative $25.7 billion over the past three months as the two dominant Asian tech exporters benefit from a global surge in AI-related investments. South Korea's shareholder-friendly reforms, political stability, and robust corporate fundamentals lured investors in 2025 after a dreary performance last year, though recent concerns over reforms to tax policy are posing new challenges. Foreign investors also net bought $499 million worth of Thai equities in July, the first month of inflows since September last year, as they scooped up stocks at relatively cheap valuations after a prolonged period of heavy selling. Even so, Thailand's uncertain political climate, challenging macroeconomic conditions, and an unnecessarily strong currency that undermines export competitiveness continue to impede any buildup of positions on these equities. Thailand's benchmark SET index surged 14% in July — its best month since November 2020 — but still not enough to erase steep losses suffered earlier in the year. The index remains 10% in the red, ranking among the region's worst performers. "We are cautious and underweight on Thailand as it remains in a fairly precarious position: high household debt, limited government spending, an uncertain political environment, and external negative events such as the conflict with Cambodia," said Kenneth Tang, senior portfolio manager at Nikko Asset Management. "If Thailand can settle these issues, it will clear up the path for its recovery." Indian stocks experienced sharp outflows of over $2 billion in July, the highest since February this year and snapping a three-month streak of net purchases. Indonesia and the Philippines also logged net outflows of $570 million and $29 million, respectively, last month, while Vietnam attracted $326 million as investors bet on the country's strong growth prospects after it secured a comfortable tariff rate with the United States. (Reporting by Sameer Manekar and Gaurav Dogra in Bengaluru; Editing by Saad Sayeed)
Zawya
2 days ago
- Zawya
Asian stocks climb, dollar droops on Fed easing bets
TOKYO: Asian equities rose on Thursday, with Japanese shares hitting a record high, as tech-led gains on Wall Street, upbeat earnings and growing expectations for U.S. rate cuts boosted sentiment. The prospect of a meeting between U.S. President Donald Trump and Russian President Vladimir Putin over the war in Ukraine also underpinned sentiment, benefitting the euro, while weighing on oil prices as traders gauged the outlook for sanctions on Moscow. Sterling held its ground at a one-week high going into the Bank of England's policy announcement later in the day, with a quarter-point cut widely expected, and the focus falling on a possible three-way split within the board. At the same time, markets largely shook off Trump's latest tariff threats, including an additional 25% tariff on India over purchases of Russian oil and a threatened 100% duty on chips. Japan's broad Topix index rose 0.9% to reach an all-time high, with the more tech-focused Nikkei also gaining by about the same margin. Taiwan's stock benchmark surged 2.3% to a more than one-year peak. South Korea's KOSPI added 0.6%. Hong Kong's Hang Seng rose 0.4%, and mainland Chinese blue chips advanced 0.3%. Australian shares edged slightly lower after hitting a record high on Wednesday. U.S. stock futures were buoyant, with those for the S&P 500 up 0.3% and those for the Nasdaq also rising 0.3%. On Wednesday, the S&P 500 climbed 0.7% and the Nasdaq Composite jumped 1.2%. "Wall Street seems to have gotten its mojo back," analyst Kyle Rodda wrote in a note. "However, there are persistent risks to the downside. Downside surprises in official data are increasing," he said. "Valuations are also stretched, with forward price to earnings hovering around the highest in four years. And trade uncertainty persists." The U.S. dollar remained lower against major peers on Thursday, with expectations of easier policy from the Federal Reserve stoked both by some disappointing macroeconomic indicators - not least Friday's payrolls report - and Trump's move to install new picks on the Fed board that are likely to share the U.S. President's dovish views on monetary policy. Focus is centring on Trump's nomination to fill a coming vacancy on the Fed's Board of Governors and candidates for the next chair of the central bank, with current Chair Jerome Powell's tenure due to end in May. The dollar index, which gauges the currency against the euro, sterling and four other counterparts, gained slightly to 98.245, after dropping 0.6% on Wednesday. The euro was little changed at $1.1657, following the previous session's 0.7% jump. Sterling was steady at $1.3356. The BoE looks poised to cut interest rates for the fifth time in 12 months later on Thursday, but nagging worries about inflation are likely to split its policymakers and cloud the outlook for its next moves. Two Monetary Policy Committee members may push for a half-point rate cut, and two may lobby for no change. The dollar added 0.1% to 147.53 yen. Gold gained 0.4% to around $3,382 per ounce, buoyed by the weaker dollar. Crude oil clawed back some losses from Wednesday, when both Brent and West Texas Intermediate slid about 1%. Brent crude futures were last up 20 cents, or 0.3%, at $67.09 a barrel, while U.S. West Texas Intermediate crude gained 22 cents, or 0.3%, to $64.57 a barrel. (Reporting by Kevin Buckland; Editing by Jacqueline Wong)
